

Applicant : George P. Vlasuk et al.
Serial No. : 09/498,556
Filed : February 4, 2000
Page : 2 of 7

Attorney's Docket No.: 17456-007008

Specification:

Replace the priority information on page 1 of the specification with

OK
LM
9/30/04

This application is a continuation of U.S. Serial No. 08/809,455, filed April 24, 1997, now U.S. Patent No. 6,090,916, which was a 371 of PCT/US95/13231, filed October 17, 1995 and a continuation-in-part of U.S. Serial Nos. 08/461,965, now U.S. Patent No. 5,872,098, 08/465,380, now U.S. Patent No. 5,863,894, 08/486,397, now U.S. Patent No. 5,866,542 and 08/486,399, now U.S. Patent No. 5,866,543, all filed June 5, 1995, each of which is a continuation-in-part of U.S. Serial No. 08/326,110, now U.S. Patent No. 5,945,275, filed October 18, 1994, the disclosures of all of which are incorporated herein by reference.

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-282 (Cancelled).

OK
LM
9/30/04

283. (Newly added) An isolated protein having anticoagulant activity and having one or more Nematode Anticoagulant Protein (NAP) domains, wherein each NAP domain includes the sequence:

Cys-A1-Cys-A2-Cys-A3-Cys-A4-Cys-A5-Cys-A6-Cys-A7-Cys-A8-Cys-A9-Cys-A10

(FORMULA III), wherein

- (a) A1 is an amino acid sequence of 7 to 8 amino acid residues;
- (b) A2 is an amino acid sequence;
- (c) A3 is an amino acid sequence of 3 amino acid residues and has the sequence Asp-A3_a-A3_b wherein A3_a and A3_b are independently selected;
- (d) A4 is an amino acid sequence having a net anionic charge;